HUTCHMED Initiates Global Trial of ATTC Candidate

Summary by AI BETAClose X

HUTCHMED has initiated a Phase I/IIa global clinical trial for HMPL-A580, a novel Antibody-Targeted Therapy Conjugate (ATTC) designed to simultaneously inhibit the PI3K/PIKK pathway and EGFR signaling in patients with solid tumors. This marks HUTCHMED's second clinical candidate from its ATTC platform, which leverages a PI3K/PIKK small-molecule inhibitor payload linked to an anti-EGFR antibody. The trial, which began on March 4, 2026, will evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy of HMPL-A580 in China and the US, with preclinical data suggesting synergistic anti-tumor activity.

Disclaimer*

UK 100

Latest directors dealings